The S&P 500 ticked 0.3% higher on Wednesday, July 16, 2025, as President Trump sought to ease concerns that a dismissal of ...

Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...

Discover Johnson & Johnson's Q2 2025 earnings insights with raised guidance and strategic growth in Oncology & MedTech.

Johnson & Johnson (NYSE:JNJ) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised ...

Johnson & Johnson shares surged Wednesday after the company reported second-quarter results that topped estimates and the company lifted its full-year outlook.

Food insecurity is not only linked with, but directly causes symptoms of anxiety and depression, according to research published in the open access ...

Adjusted earnings per share for the quarter to June 29 fell to $2.77 from $2.82 in the same period a year ago, and topped the ...

Johnson & Johnson boosted its full-year outlook as it posted better-than-expected profit and sales in the second quarter.

Now, after setting an innovative medicines sales record in the year’s second quarter, it appears J&J’s confidence was well placed.

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and ...

Johnson & Johnson kicked off Q2 2025 pharma earnings season with a bang Wednesday, adding $2 billion to the midpoint of its ...